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Objective: To evaluate the prevalence of b3-adrenergic receptor (ADRB3) Trp64Arg polymorphism and its relationship with the
metabolic syndrome in severe obesity.
Design: Cross-sectional outpatients study.
Patients and methods: In 265 (100 men) severely obese non-diabetic subjects and 78 (25 men) healthy volunteers, genomic
DNA was isolated from peripheral leukocytes. In obese patients, plasma concentrations of leptin, lipids, glucose and insulin, the
homeostasis model assessment index and blood pressure have been measured. The Trp64Arg mutation was identified with the
real-time TaqMan method.
Results: Neither genotype distribution nor allele frequency differed between the two groups. The metabolic syndrome
prevalence was 59% in obese subjects, and was higher in men than in women (65 vs 55%: P¼0.03). The body mass index
(BMI) was related to age tertiles (b¼0.08; Po0.001; multiple linear regression) in Trp64Arg-positive obese subjects.
Conclusion: We confirm the high prevalence of the metabolic syndrome among severely obese subjects. ADRB3 polymorphism
was significantly related to insulin resistance only in obese male subjects. Moreover, increased BMI was related to age in obese
subjects with the ADRB3 polymorphism.
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Introduction
Overeating and physical inactivity, combined with genetic
predisposition, are the main causes of obesity in humans.
Efforts to identify obesity genes have traditionally focused
on white and brown adipose tissues (Arner, 2000), which
play a crucial role in regulating energy storage and fuel
mobilization in mammals. The ADRB3 gene is involved in
regulating thermogenesis and lipolysis (Arch and Kaumann,
1993). In fact, its stimulation by b-adrenergic agonists
activates adenylate cyclase, which, in turn, increases in-
tracellular concentrations of cyclic AMP thereby causing
increased lipolysis in white adipose tissue and heat produc-
tion in brown adipose tissue (Zaagsma and Nahorski, 1990;
Lofontan and Berlan, 1993; Katzmarzyk et al., 1999).
In humans ADRB3 is highly expressed in visceral fat (Krief
et al., 1993) and is responsible for increases in lipolysis and
the delivery of free fatty acid into the portal vein (Lo¨nnqvist
et al., 1995). A mutation in codon 64 of ADRB3 leads to
replacement of tryptophan by arginine (Trp64Arg), which is
located in the first intracellular loop of ADRB3, and might
affect binding to noradrenalin and coupling to G proteins in
adipose cells (Walston et al., 1995). Therefore the Trp64Arg
mutation appears to affect at least some of the receptor’s
functions in vivo (Candelore et al., 1996; Pietri-Rouxel et al.,
1997; Snitker and Odeleye, 1997) and in vitro (Hoffstedt et al.,
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1999), which would account for decreased lipolysis in white
adipose tissue (Katzmarzyk et al., 1999).
The Arg64 variant of the ADRB3 gene has been associated
with an earlier onset of type II diabetes mellitus and a
decreased acute insulin response to glucose (Walston et al.,
2000). The pancreas is a major site of ADRB3 gene
expression, and cell transfection with Arg64 was associated
with a decrease in glucose-dependent insulin secretion
(Perfetti et al., 2001). ADRB3 gene is therefore involved in
several metabolic pathways which could be directly or
indirectly linked to energy balance and body weight
regulation. However, the association between the Trp64Arg
ADRB3 polymorphism and obesity is still controversial, in
particular, in Caucasian populations. About half the studies
identified an association between the mutation and excess
body fat mass (Kadowaki et al., 1995; Walston et al., 1995;
Widen et al., 1995; Yoshida et al., 1995; Luke et al., 1997),
whereas the other half did not (Awata and Katayama, 1996;
Gagnon et al., 1996; Ueda et al., 1997; Shiwaku et al., 1998).
The Trp64Arg mutation was found to predict a greater
tendency for abdominal adiposity and high blood pressure
with advancing age in a large working population of males
from South Italy (Strazzullo et al., 2001). It seems to have a
weak effect on actual body mass index (BMI); indeed, only a
barely statistically significant difference emerged from meta-
analyses (Allison et al., 1998; Fujisawa et al., 1998; Kurokawa
et al., 2001). These divergent results may be, at least in part,
due to population sampling variations, differences in
ethnicity, sex, age and degree of excess body fat.
Morbid obesity (BMI 440 kg/m2), which is increasing in
adults and children (Flegal et al., 2002), has a strong genetic
component (Price et al., 1990; Adams et al., 1993). Conse-
quently, there patients may represent a good sample in
which to evaluate the role of ADRB3 polymorphisms in
obesity predisposition.
Of the two studies that looked for a link between the
ADRB3 Trp64Arg polymorphism and severe obesity, one
identified an association (Clement et al., 1995) and the other
did not (Oksanen et al., 1996). Furthermore, the association
between the metabolic syndrome (Grundy et al., 2005) and
the ADRB3 polymorphism has not been evaluated in severely
obese subjects.
We have investigated the association of the Trp64Arg
polymorphism with obesity-related phenotypes, in particular,
with the metabolic syndrome in a homogenous population of
severely obese (BMI440 kg/m2) subjects from South Italy. Our
aim was to determine the prevalence of the Trp64Arg
mutation in severe obesity, and to establish whether this
mutation is related with the metabolic syndrome.
Subjects and methods
Subjects
The study population consisted of 265 (100 men, 165
women) severely obese non-diabetic subjects (type III
obesity) recruited from the outpatient obesity clinic of the
Department of Internal Medicine, ‘Federico II’ University
Hospital in Naples. All subjects had normal liver, kidney and
thyroid functions, and none had a history of excessive
alcohol intake. No subject was taking antihypertensive drugs
or substances known to affect basal metabolic rate, or
glucose or lipid metabolism. We evaluated the frequency of
the ADRB3 Trp64Arg polymorphism in the obese subjects
and in 78 (25 men 53 women) healthy normal weight
volunteers recruited from blood donors living in the same
area of South Italy. Obese subjects and controls gave their
informed consent to the study, which was approved by the
Ethics Committee of our University Hospital.
Anthropometric and metabolic measurements
Weight and height were measured and the BMI calculated as
the body weight (kg) divided by the squared height (m2).
Systolic and diastolic blood pressures were measured after
the subject had rested for 5 min in a sitting position. After
a 10-h overnight fast, 20 ml of blood were collected and
immediately centrifuged at room temperature. Plasma
glucose was measured by the hexokinase method adapted
for an autoanalyzer (Hitachi Modular, Tokyo, Japan). Total
cholesterol, triglycerides and high-density lipoprotein (HDL)
cholesterol were determined by standard enzymatic methods
(Hitachi Modular). Low-density lipoprotein (LDL) cholester-
ol was calculated using the Friedewald formula (Friedewald
et al., 1972). Serum insulin was measured by the chemilu-
minescence method (Immulight 2000; Medical System,
Genova, Italy). Serum leptin concentrations were measured
in duplicate in obese and control individuals with a human
leptin enzyme immunoassay (Linco Research, St. Charles,
MO, USA). Insulin resistance was estimated according to the
homeostasis model assessment (HOMA-IR) method from
fasting glucose and insulin concentrations, according to
the formula: insulin (mU/ml) glucose (mmol/l)/22.5
(Matthews et al., 1985). Metabolic syndrome was diagnosed
considering the combination of three out of five risk factors
according to AHA criteria (Grundy et al., 2005).
Genotyping
Genomic DNA was extracted from peripheral leukocytes
with a widely used procedure (Nucleon BAAC-2, Amersham,
Little Chalfont, Buckinghamshire, UK). The ADRB3 Trp64Arg
polymorphism was identified by the real-time TaqMan
method (Applied Biosystems, Foster City, CA, USA) and
two fluorescent probes: one specific for the wild-type allele,
labeled with the VIC fluorescent reporter dye, and the other
complementary to the mutant allele, labeled with the FAM
marker. We used the Primer Express program to design the
polymerase chain reaction (PCR) primers forward 50-
GCAACCTGCTGGTCATCGT-30, reverse 50-GTTGGTCATGGT
CTGGAGTCT-30; MGB TaqMan probes VIC-CATCGCCTGGA
CTC-Q-MGB and FAM-ATCGCCCGGACTC-Q-MGB where
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MGB is the minor groove binder, a molecule that stabilizes
the duplex DNA probe thereby increasing the ability of the
hybridization probe to discriminate the single-nucleotide
polymorphism). Reaction mixtures were assembled in a
384-well plate using a Biomek 2000 Workstation (Beckman
Instruments, Fullerton, CA, USA). Each consisted of: 40 ng of
genomic DNA, 36 nM primers, 8 nM probes and 2.5 ml
TaqMan Universal Master Mix (Applied Biosystems) in a
total reaction of 5ml. Negative and positive controls (i.e. no
DNA, homozygote and heterozygote samples for the
Trp64Arg previously typed by sequence analysis on ABI
Prism 3100 Genetic Analyzer, Applied Biosystems) were also
tested for internal quality control. Real-time PCR was carried
out on an ABI Prism 7900 HT instrument with the Sequence
Detection System (SDS 2.1) and the SDS Enterprise Database
(Applied Biosystems). The amplification protocol consisted
of: 501C for 2 min; 951C for 10 min; 921C for 15 s, 601C for
1 min for 40 cycles; final extension at 601C for 1 min; final
soak at 251C. The genotypes were determined without prior
knowledge of the subjects’ status (Afonina et al., 1997; Livak,
1999; Kutyavin et al., 2000).
Statistics
Descriptive summary statistics for continuous variables are
expressed as mean7s.d. Before inferential analysis, data on
continuous variables were normalized with logarithm trans-
formation. Allele frequencies for each polymorphic site were
estimated by the gene-counting method. We used the w2 test
to compare genotype frequencies. A multiple linear regres-
sion analysis, adjusted for sex as potential confounder, was
carried out to examine whether the relationship between age
and BMI depended on ADRB3 genotype. We used linear
regression analyses (with a control for the effects of age,
gender and BMI) to examine the association of the other
continuous variables (leptin, lipids, glucose, insulin, HOMA
index and blood pressure). The association was analyzed
using an additive model in which the differences (coefficient
b) are expressed as a function of the number of copies of the
more common allele. The interaction between genotype
(wild type or the ADRB3 variant) and gender for biochemical
measures of metabolic syndrome was tested with a general-
ized linear model in which genotype was the fixed variable
and gender, age and BMI covariate factor as appropriate.
We carried out also a principal component analysis using
the correlation matrix of the variables related to insulin
resistance dyslipidemia (insulin, triglycerides and HDL
cholesterol). According to a generalized linear model
adjusted for BMI, ANOVA was carried out with the score
calculated from the first principal component accounting for
51% of the variance. The Statistical Package of Social
Sciences (SPSS Inc., Chicago, IL, USA) for Windows, version
12.0 was used for statistical analyses.
Results
The mean age of obese subjects was 32. 6711.6 years and
their mean BMI was 48.277.5 kg/m2.
Table 1 lists genotype distributions and allele frequencies of
the ADRB3 Trp64Arg polymorphism in obese patients and
controls. There were no homozygotes. Neither genotype
distribution nor allele frequency differed between obese
subjects and controls or between men and women. Genotype
frequencies were in accordance with Hardy–Weinberg expec-
tations in the obese (P¼0.99) and control (P¼0.99) groups.
At multiple linear regression analysis, BMI was signifi-
cantly related to age (b¼0.08; Po0.001) only in patients
carrying the Trp64Arg mutation. The prevalence of the
metabolic syndrome was 59% in the group of obese subjects,
and was significantly higher in males than in females (65
vs 55%: P¼0.03). Table 2 shows the results of the multiple
linear regression analysis of the association between the
metabolic variables measured and ADRB3 genotype in
patients. LDL cholesterol was slightly higher in the wild-
type group approaching statistical significance (P¼0.06); no
significant differences were observed between wild-type
and carriers.
Figure 1 shows the results of monovariate (panels a–c) and
multivariate (d) analyses of the effect of the gender–
genotype interaction on insulin resistance and related
dyslipidemia. Only in the patients with the Trp64Arg
Table 1 Genotypes and allele frequencies of the Trp64Arg ADRB3 polymorphism in obese patients
Obese subjects Controls P**
Men (n¼100) Women (n¼165) P* Men (n¼25) Women (n¼53) P*
ADRB3 Trp64Arg 0.40
Trp/Trp 96 (96%) 156 (94.6%) 24 (96%) 48 (90.6%)
Trp/Arg 4 (4%) 9 (5.4%) 1(4%) 5(9.4%)
Arg/Arg 0 0 0.82 0 0 0.70
Allele frequencies 0.26
Trp64 0.98 0.97 0.98 0.95
Arg64 0.02 0.03 0.61 0.02 0.05 0.46
Values were compared with w2 analysis; *Men vs Women; **Obese vs Controls.
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Table 2 Multiple linear regression analysis of the association between metabolic variables and ADRB3 genotypes in obese patients
ADRB3 genotypes Multiple linear regression analysis
Trp/Trp (n) Trp/Arg (n) Beta (95% CI) P
Glucose (mmol/l) 5.2271.147 (229) 4.9370.50 (13) 0.05(0.03–0.14) 0.21
HDL cholesterol (mmol/l) 1.1670.28 (229) 1.1370.28 (13) 0.03 (0.01–0.15) 0.69
HDL/total cholesterol (%) 25.176.5 (229) 27.3711.9 (13) 0.04 (0.19–0.11) 0.59
LDL cholesterol (mmol/l) 1.2970.12 (229) 1.1870.57 (13) 0.16 (0.01–0.33) 0.06
Triglycerides (mmol/l) 1.4670.70 (229) 1.4871.34 (13) 0.09 (0.17–0.36) 0.49
Insulin (pmol/l) 130.8765.4 (233) 164.47231.0 (13) 0.15 (0.13–0.43) 0.29
HOMA 5.172.9 (231) 6.078.3 (13) 0.21 (0.10–0.51) 0.18
Leptin (ng/ml) 110.9763.0 (149) 112.1754.8 (7) 0.13(0.31–0.57) 0.55
SBP (mm Hg) 126716 (246) 130713 (12) 0.03 (0.09–0.03) 0.39
DBP (mm Hg) 80710 (246) 8178 (12) 0.01 (0.08–0.06) 0.77
Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure.
The numbers in parentheses are the number of patients; values are not adjusted mean7s.d. (n). Differences (b) between genotypes are adjusted for age, sex and BMI
in generalized equation models. Differences were analyzed using an additive model and are expressed per copy of the most frequent allele (the allele listed first), in
terms of the natural logarithm of the relevant variable.
0
  30
60
90 
120
150
180
210
Trp64Trp Trp64Arg
Men
Women
In
su
lin
 (p
mo
l/L
)
0
 0.23
 0.45
     0.68
 0.90
 1.13
 1.35
 1.58
1.80
 2.03
 2.26
Trp64Trp Trp64Arg
Men
Women
Tr
ig
ly
ce
rid
es
 (m
mo
l/L
)
0
0.25
0.51
0.78
1.03
1.30
1.55 
Trp64Trp Trp64Arg
H
D
L 
Ch
ol
es
te
ro
l
(m
mo
l/L
) 
Men
Women
-0.4
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
Trp64Trp Trp64Arg
Pr
in
ci
pa
l c
om
po
ne
nt
 sc
or
e
Men
Women
n.s
n.s.
n.s.
n.s.
P<0.05 
P<0.001
P<0.001 
P<0.001 
a b
c d
Figure 1 Monovariate (a–c) and multivariate (d) analysis of the effect of the gender–genotype interaction on insulin resistance-related
dyslipidemia. In males with severe obesity (n¼100: wild type, n¼96; heterozygote, n¼4), concentrations of insulin (Po0.001) and triglyceride
(Po0.05) were significantly higher and HDL cholesterol significantly lower (Po0.001) than in obese females (n¼165: wild type, n¼156;
heterozygote, n¼9) (a–c). The differences were more marked in Trp64Arg-positive subjects; and the gender–genotype interaction was
statistically significant (Po0.05) for insulin. Principal component analysis of the three variables was calculated using a component that accounts
for 51% of variance. The principal component score, which reflects insulin resistance, was higher in obese males Trp64Arg carriers (Po0.001),
with a significant gender–genotype interaction (Po0.05) (Figure 1d).
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genotype, insulin and triglyceride levels were significantly
higher (Po0.001 and Po0.05, respectively), and HDL
cholesterol was significantly lower (Po0.001) in men than
in women (panels a–c). The interaction between gender and
genotype was statistically significant only for insulin
(P¼0.037). The principal component analysis of the three
variables (insulin, triglycerides and HDL) was calculated
using a component that accounts for 51% of variance. The
principal component score, which reflects insulin resistance,
was significantly higher in obese males Trp64Arg carriers
(Po0.001), with a significant gender–genotype interaction
(Po0.026) (Figure 1d).
Discussion
This study was carried out in a population of severely obese
patients, where a strong polygenic component is expected
(Price et al., 1990; Adams et al., 1993) thus representing a
target population for genetic studies in human obesity
(Clement et al., 1995; Oksanen et al., 1996).
The prevalence of the ADRB3 Trp64Arg polymorphism in
our obese subjects did not differ from that in the control
subjects or from the prevalence already identified in adult
male employers of the Olivetti plant in South Italy
(Strazzullo et al., 2001). In the Que´bec Family Study cohort
(1268 individuals from French-Canadian families) the allelic
frequency for the carriers and non-carriers of Trp64Arg
were 0.92 and 0.08, respectively (Gagnon et al., 1996). In a
subsample of obese women (37–60 years old; BMI430 kg/m2)
of this Canadian population, the allelic frequency of the
Arg64 was 0.07 versus 0.04 in controls (Gagnon et al., 1996).
Furthermore, no significant difference in the frequency of
the Trp64Arg polymorphism was observed between obese
and lean subjects in German and Finnish studies (Oksanen
et al., 1996; Evans et al., 2000). In particular, the frequency of
the Arg64 allele did not differ in Finnish subjects with severe
obesity (BMIX40 kg/m2; 9.1%) and in lean healthy control
subjects (8.9%) (Oksanen et al., 1996).
In our study, there were no Arg64Arg homozygote in either
the obese or the control group, and heterozygote were B5%
in both groups in accordance to the literature.
Our data show that Trp64Arg polymorphism is signifi-
cantly related to weight gain with age thus confirming the
results of the Olivetti study carried out in a male working
population from the same geographical area (Strazzullo et al.,
2001). Overall, these observations are in line with the
finding that low fat oxidation over time predicts a mild,
progressive increase of body fat (Seidell et al., 1992; Astrup
et al., 1997; Marra et al., 2004). It is therefore conceivable
that impaired ADRB3 activity may promote body weight
gain by reducing lipolysis in adipose tissue and possibly by
reducing thermogenesis, that is reduced as a consequence of
aging. Indeed an impairment with age of adrenergic-related
thermogenesis could be further increased by ADRB3 poly-
morphism (Seals and Bell, 2004).
More convincing association between ADRB3 polymor-
phism and BMI has been reported in Asian population where
the prevalence of ADRB3 polymorphism is higher than in
Caucasian population (Fujisawa et al., 1998; Thomas et al.,
2000; Kurokawa et al., 2001).
In our severely obese subjects, the ADRB3 polymorphism
was not significantly associated with the metabolic syn-
drome, apart from insulin resistance related dyslipidemia
in males. Cross-sectional analyses based on data from the
Que´bec Family Study did not reveal any difference in
glucose, insulin and resting blood pressure values between
carriers versus non-carriers of the Trp64Arg mutation
(Gagnon et al., 1996). On the other hand, in Japanese
subjects it has been reported that the ADRB3 polymorphism
has been associated with insulin resistance but not with
dyslipidemia (Kadowaki et al., 1995).
The data about the effect of the ADRB3 mutation on serum
triglycerides appear not conclusive. In three studies, the
Arg64 allele was unrelated to the plasma lipid profile (Widen
et al., 1995; Moriarty et al., 1997; Ukkola et al., 2000).
Another study on the mutation carried out in young healthy
Danes reported an increase in triglycerides and LDL
cholesterol in Arg64 homozygotes (Urhammer et al., 1996).
In a Spanish study, ADRB3 gene variants were significantly
related to triglyceride and total cholesterol concentrations in
men (Corella et al., 2001).
In conclusion in our population of severely obese patients
the prevalence of the ADRB3 polymorphism did not differ
from that of the control group. On the other hand, the
polymorphism was associated in obese patients with a
significantly higher age-related BMI. The prevalence of MS
was as expected, quite high in our obese subjects and
irrespective of the ADRB3 gene polymorphism. However,
insulin resistance was found higher in obese males carrying
the ADRB3 mutation. Further data from prospective studies
are required to clarify the relationship between aging and
increased BMI as related to ADRB3 polymorphism as well as
other thermogenesis-related genes.
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